0001104659-26-036451
SEC filingCytosorbents delivered modest revenue growth and significantly narrowed losses for fiscal 2025, while executing restructuring actions to advance its path to profitability.
For the full 2025 fiscal year, Cytosorbents reported 4.1% year-over-year revenue growth to $37.1M, with gross profit rising 5.4% to $26.5M for a 71.5% gross margin. The company’s net loss narrowed 60.4% year-over-year to $8.2M, an improvement driven primarily by reduced clinical trial costs following the completion of the STAR-T clinical trial, lower grant-funded project expenses, and additional cuts to other clinical and product development programs. The company also recorded a foreign currency gain tied to the appreciation of the Euro relative to the U.S. dollar, which further supported the improved bottom line. These gains were partially offset by higher interest expenses, as the company incurred a full year of interest on its credit facility, which was first initiated in the third quarter of 2024.